報價延遲最少15分鐘:2025/03/28 05:18 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.3809 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.76/-1.03
|
|
企業價值
121.17M
|
| 資產負債 |
|
每股賬面淨值
0.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 05:18 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. |